ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

WCRX Warner Chilcott

0.00
0.00 (0.00%)
Share Name Share Symbol Market Stock Type
Warner Chilcott WCRX London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% -
Open Price Low Price High Price Close Price Previous Close
more quote information »

Warner Chilcott WCRX Dividends History

No dividends issued between 02 May 2014 and 02 May 2024

Top Dividend Posts

Top Posts
Posted at 20/9/2004 10:52 by samuri
Hadn't realised people not seen this a.m's news.

Craigavon, Northern Ireland/Rockaway, New Jersey, USA - 20 September 2004:
Warner Chilcott PLC ('Warner Chilcott') (LSE: WCRX, Nasdaq: WCRX).



The board of Directors has noted the recent speculation in the media regarding
the possibility of an offer for the Company. The board can confirm that they
have received an approach from a consortium of private equity houses which may
or may not lead to an offer, at an indicative cash price of 800p per share,
being made for the entire issued share capital of Warner Chilcott.



The board, other than Roger Boissonneault, the Chief Executive Officer, who in
view of the nature of the approach is not currently participating in these
deliberations, is considering the appropriate response to this approach.



The board wish to make clear that the approach they have received is preliminary
in nature and is subject to, inter alia, various pre-conditions including
financing and due diligence. There can be no certainty that an offer will
actually be made. Furthermore, there can be no certainty as to the level of any
offer. A further announcement will be made in due course, if appropriate.
Posted at 11/8/2004 09:14 by samuri
Merrills (Co's broker & advisor) have reiterated their buy with a prospective eps of 60p. This gives a pe of 9.6 at 577p, growth forecast at 15% giving a peg of 0.64. Sector av pe >15 therefore I believe that WCRX is undervalued and has room for upside move.
Also bought back 1.5m shares yesterday.
Posted at 30/7/2004 17:21 by willyk
Warner Chilcott PLC
30 July 2004


WARNER CHILCOTT PLC

WARNER CHILCOTT RECEIVES POSITIVE COURT DECISION ON SARAFEM(R) LITIGATION


Craigavon, Northern Ireland, UK/Rockaway, New Jersey, US, July 30, 2004 - Warner
Chilcott PLC ('Warner Chilcott') (LSE: WCRX.L, Nasdaq: WCRX), today announced
that it has received a decision from the United States District Court for the
Southern District of Indiana concerning its patent litigation dispute with Teva
Pharmaceuticals (Teva).

The case was initiated in response to an abbreviated new drug application (ANDA)
filed by Teva to market a generic version of Sarafem(R), the US sales and
marketing rights of which were acquired from Eli Lilly & Co. (Lilly) by Warner
Chilcott in January 2003. Sarafem is indicated for the treatment of
Pre-Menstrual Dysphonic Disorder (PMDD).

Under the ruling, Judge Barker has found in favour of Lilly and Warner Chilcott,
and upheld the validity of the Sarafem(R) patent. As a result, injunctive
relief is available to Warner Chilcott until the expiration of the patent in May
2008.

Commenting on the court's decision, Roger Boissonneault, CEO of Warner Chilcott
said, 'We are extremely pleased to hear that the court has found in our favour
in this case. Sarafem(R) is, and will continue to be, an important product for
us and following this decision, we will continue to move forward with our plans
to develop the PMDD market and introduce new products under the Sarafem(R) brand
'
Posted at 20/7/2004 09:31 by samuri
Very aggravating I agree, particularly after such good figures for March. Maybe there is a fear that the momentum cannot be sustained. The only answers I can suggest are:

1. Pfizers warning (and another US pharma I think) last week could impact WCRX, as bulk of revenues now generated in US.
2. JP Morgan have reiterated an overweight stance on AstraZ ahead of their results with a target price of £32. This may have prompted investors to switch from WC to AZ.
3. Market generally continues to fall.

From a charting point of view the RSI is now less than 19 indicating a very oversold position. Results for June quarter should be out mid Aug and one hopes for continued good performance with no surprises.
Posted at 20/7/2004 09:25 by matthu
I look forward to their reply. Meanwhile, WCRX have been tipped by Goodbody Stockbrokers:



Goodbody Stockbrokers is among the growing list of fans behind (Elan). Recently tipped to hit $45 Goodbody's Ian Hunter is a bit more phlegmatic about the stock, though positive it will go above $31.

Mr Hunter says that the group is beginning to return to prosperity having eliminated the high financial risks that caused its share price to plunge in 2002.

... In his assessment of the other publicly-quoted pharmaceutical stocks Mr Hunter tips Warner Chilcott as the other share buy.

Your Recent History

Delayed Upgrade Clock